AI assistant
Sending…
SELLAS Life Sciences Group, Inc. — Director's Dealing 2012
Jan 10, 2012
33651_dirs_2012-01-09_069f7e26-f864-4682-b5ca-ddebdbf9a687.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2011-12-31
Reporting Person: SCHWARTZ MARK W. (EVP Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-12-31 | Common Stock, par value $.0001 | J | 12924 | $0.4 | Acquired | 350585 | Direct |
Footnotes
F1: Pursuant to the Issuer's Employee Stock Purchase Plan.
More from SELLAS Life Sciences Group, Inc.
Regulatory Filings
2026
Jun 2
Report Publication Announcement
2026
May 12
Interim / Quarterly Report
2026
May 12
Major Shareholding Notification
2026
Mar 27
Capital/Financing Update
2026
Mar 20
Major Shareholding Notification
2026
Jan 30
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9